Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

▤ Summary

Firefly Neuroscience announced that its AI-driven Evoke System identified a novel electrophysiological biomarker for PTSD from FDA-cleared brain scan data. The result builds on Firefly’s public-private partnership with the U.S. Department of War to support assessment and treatment for active-duty service members and veterans. Firefly says its deep learning stack on NVIDIA L40S infrastructure enabled large-scale analysis of EEG and ERP waveforms and strengthened its position in defense health, pharma, and clinical psychiatry. The company also highlights that the finding could support more objective PTSD assessment across military and civilian use cases.

▦ Linked Companies